PhoenixBio Co., Ltd. (6190.T) Stock
PhoenixBio Co., Ltd.

Company profile
PhoenixBio reported revenue of 1.54 billion JPY for fiscal year 2025, down 10.1% from fiscal year 2024. USA was its largest region in fiscal year 2025, with 73% of revenue. Our analysis of its filings shows revenue shrinking from 2.12 billion JPY in fiscal year 2023 to 1.54 billion JPY in fiscal year 2025, 14.8% a year on average. PhoenixBio reports about 69 full-time employees.
What stands out
- It reported a net loss of 448.93 million JPY in fiscal year 2025, after a profit of 26.38 million JPY in fiscal year 2024.
Figures from company filings; latest fiscal year ended March 31, 2025.
About PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Largest shareholders
- Sanwa Starch Co., Ltd.31.28%
- Shunichi Morimoto12.41 %12.41%
- Institute of Immunology Co., Ltd.3.16%
- Ryosuke Matsui2.453 %2.45%
- Eiken KK2.16%
Share of the company, as of September 25, 2026
Leadership
- Takashi Shimada — President, CEO & Representative Director, 65
- Yoshinori Fujii — Director & Executive Director of Accounting, 54
- Yasuhiro Tamura — Senior MD, Executive Director of Administration & Director, 67
- Tomoyo Mukaitani Ph.D. — Executive Director of Production & R&D and Director, 63
- Masakazu Kakuni Ph.D. — Executive Director of Business Development & Quality Control and Director, 53
How much revenue does PhoenixBio make?
PhoenixBio reported 1.54 billion JPY in revenue for fiscal year 2025, down 10.1% from 1.72 billion JPY in fiscal year 2024.
Where does PhoenixBio make most of its revenue?
USA: 73% of revenue by region in fiscal year 2025, followed by Japan (17%).
What companies are similar to PhoenixBio?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Create Medic Co., Ltd. (5187.T), Cyfuse Biomedical K.k. (4892.T), atect corporation (4241.T).
Has PhoenixBio made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 238.00 million JPY; FY2022, a loss of 387.97 million JPY; FY2023, 493.33 million JPY; FY2024, 26.38 million JPY; FY2025, a loss of 448.93 million JPY. It reported a net loss in 3 of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “PhoenixBio Co., Ltd. (6190.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/6190.T